Krystal Biotech, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 |
| Operating income | $161.3M | $65.7M | -$109.6M | -$145.2M | -$68.3M |
| Operating expenses | $227.8M | $224.8M | $160.3M | $145.2M | $68.3M |
| Cash from operations | $200.9M | $123.4M | -$88.8M | -$100.6M | -$47.9M |
| Capital expenditure | $12.0M | $4.2M | $11.8M | $53.0M | $68.3M |
| Free cash flow | $188.9M | $119.2M | -$100.6M | -$153.5M | -$116.3M |
| Impairments | — | — | $0 | $0 | $0 |
| Total assets | $1.3B | $1.1B | $818.4M | $558.5M | $626.3M |
| Total liabilities | $114.2M | $109.5M | $39.7M | $36.2M | $32.7M |
Shares outstanding 29.5M · Free float 86.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.